Published in Medicine and Law Weekly, June 17th, 2005
"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapy that preferentially induces apoptosis in cancer cells. However, many neoplasms are resistant to TRAIL by mechanisms that are poorly understood. Here we demonstrate that human breast cancer cells, but not normal mammary epithelial cells, are dramatically sensitized to TRAIL-induced apoptosis and caspase activation by peroxisome proliferator-activated receptor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly